https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
LR was also associated with more major complications ( .001) and longer hospital stay ( .001). Subgroup analyses demonstrated that LR and RFA had similar efficacy in patients with recurrent tumors less than 3 cm or patients presenting three or fewer recurrent nodules. LR could provide better long-term survival outcomes than RFA for recurrent HCC patients, while RFA has a higher safety profile. RFA can be a good alternative to LR for patients with small-sized recurrence or patients with a limited number of recurr
Like
Comment
Share
